M&As this week: Shenzhen Salubris Pharmaceuticals, USV, Sanofi

26 January 2018 (Last Updated January 25th, 2018 12:01)

Chinese pharmaceutical company Shenzhen Salubris Pharmaceuticals has agreed to purchase a 10.81% stake in a biotech company based in Changshu for CNY100m ($15.62m).

Chinese pharmaceutical company Shenzhen Salubris Pharmaceuticals has agreed to purchase a 10.81% stake in a biotech company based in Changshu for CNY100m ($15.62m).

German pharmaceutical company USV plans to acquire another generic pharmaceutical company also based in Germany.

The acquisition is expected to be completed in three months.

Healthcare company Sanofi has agreed to acquire biotechnology company Bioverativ Inc for $11.5bn.

Sanofi will buy the entire outstanding shares of Bioverativ common stock at a price of $105 a share in cash.

The acquisition will enable Sanofi to expand its specialist care portfolio.

Both the acquirer and target companies are based in the US.

Jixi Agrosino Biotech has agreed to purchase a minority stake in Taiwanese biopharmaceuticals company TLC Biopharmaceuticals (HK) (TLCHK) from Taiwan Liposome Company (TLC) for $20m.

Based in Hong Kong, Jixi is involved in the production of chemical raw materials and chemical products, while TLC is a Taiwan-based company involved in the development of novel nanomedicines.

“Healthcare company Sanofi has agreed to acquire biotechnology company Bioverativ Inc for $11.5bn.”

The acquisition will help Jixi to conduct clinical studies and commercialise TLC’s pipeline for the Chinese market.

Celgene and Juno Therapeutics (Juno) have signed a merger agreement for a consideration of $87 a share in cash, making the total consideration $9bn.

Based in the US, Celgene is a biopharmaceutical company, while Juno is a clinical-stage cell immunotherapy company also based in the US.

The merger will enable Celgene to accelerate the development Juno’s pipeline and strengthen its position in haematology.

BioCryst Pharmaceuticals and Idera Pharmaceuticals have entered a merger agreement to form a new company, which will focus on the development and commercialisation of medicines for rare diseases.

The new combined company will be renamed after the completion of the transaction and headquartered in Exton, PA.

Idera Pharma’s CEO will lead the new company, while BioCryst Pharma Chairman will act as Chairman.

The merger will enable both companies to capitalise on their collective expertise and create a comprehensive, rare disease-focused company.

Both companies involved in the transaction are based in the US.